Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

876.724
+0.1410.02%
Number of Gainers:6
Number of Losers:11
Number of Flat:- -
PE:- -
High:890.784
Open:876.583
Low:868.008
Close:876.583
Volume:316.73M
Turnover:2.28B
Market Cap:590.19B
Float Cap:489.89B

Loading ...

Ascletis Pharma Presents Preclinical Results for Weight Management Drugs at ObesityWeek 2026

MT Newswires Live
·
3 hours ago

CanSino Biologics Gets China Trial Approval to Expand Vaccine's Booster Age Range

MT Newswires Live
·
4 hours ago

Lazard Asset Management LLC Reduces Stake in SINOPHARM (01099) by 5.9856 Million Shares at HK$17.12 Each

Stock News
·
4 hours ago

Fosun Pharma Unit Gets China Nod for Tumor Imaging Drug Trial

MT Newswires Live
·
4 hours ago

CSPC Pharma Starts Phase Ib/II Trial of Cancer Drug Combination in China

MT Newswires Live
·
4 hours ago

Sihuan Pharma Says New Indication of Bireociclib Tablets Included in 2026 NRDL

Reuters
·
5 hours ago

Junshi Bio Spends Approximately HK$4.2999 Million to Repurchase 303,000 Shares on November 16

Stock News
·
5 hours ago

CSPC Pharma's SYH2051 Combined with Irinotecan Liposome Enters Phase Ib/II Clinical Trial for Advanced Solid Tumors, First Site Launched in China

Stock News
·
5 hours ago

Shanghai Fosun Pharma - Unit Got Nmpa Approval for Clinical Trial of [18f]f-SR031 Injection

THOMSON REUTERS
·
5 hours ago

CSPC Pharmaceutical - Initiates Phase Ib/Ii Trial of Syh2051 with Irinotecan Liposome in China

THOMSON REUTERS
·
5 hours ago

Fosun Pharma's FXR0906 Injection Enters Phase II Clinical Trial in China for Hypertriglyceridemia Treatment

Stock News
·
5 hours ago

CanSino Biologics - Tdscp Obtains Clinical Trial Approval in China for Ages 4 to 5 Years

THOMSON REUTERS
·
5 hours ago

Fosun Pharma Unit Wins Clinical Trial Approval for SRT-003-1 Diagnostic Drug

Stock News
·
6 hours ago

Ascletis Oral Obesity Drug Combination Shows 10.5% Weight Loss in Monkey Study

Reuters
·
6 hours ago

Sihuan Pharma Subsidiary Xuanzhu's Bireociclib Gains China Reimbursement for First-Line Breast Cancer Treatment

Reuters
·
7 hours ago

Sihuan Pharma - New Indication of Bireociclib Tablets Included in 2026 Nrdl for First-Line Hr+/Her2- Advanced Breast Cancer

THOMSON REUTERS
·
7 hours ago

JD Health International Stock Rises 1.5% in Hong Kong

Dow Jones
·
7 hours ago

Alibaba Health Information Technology Stock Rises 2.5% in Hong Kong

Dow Jones
·
7 hours ago

Sinopharm Group Stock Climbs 1.7% in Hong Kong

Dow Jones
·
7 hours ago

BYD Electronic (International) Stock Sheds 5.1% in Hong Kong

Dow Jones
·
7 hours ago